Predictive value of magnetic resonance imaging for multifocal osteonecrosis screening associated with glucocorticoid therapy. Issue 3 (3rd May 2020)

• Record Type: Journal Article
• Authors: Nawata, Kento; Nakamura, Junichi; Hagiwara, Shigeo; Wako, Yasushi; Miura, Michiaki; Kawarai, Yuya; Sugano, Masahiko; Yoshino, Kensuke; Inage, Kazuhide; Orita, Sumihisa; Ohtori, Seiji
• Is Part Of: Modern rheumatology. Volume 30:Issue 3(2020)
• Page Start: 586
• Page End: 591
• Publication Date: 2020-05-03
• Subjects: MRI screening -- osteonecrosis -- glucocorticoids -- hip -- knee; Rheumatology -- Periodicals; 616.723005
• DOI: 10.1080/14397595.2019.1623363
• Languages: English
• ISSNs: 1439-7595

Abstract

Abstract: Objectives: The goals of this study were to elucidate the distribution of multifocal osteonecrosis associated with glucocorticoid therapy using magnetic resonance imaging (MRI) and to establish a MRI screening method. Methods: Between 1986 and 2018, 107 patients underwent MRI screening of their hips, knees, shoulders and ankle joints (856 joints in total) after systemic glucocorticoid therapy. Results: Osteonecrosis was observed in hip (68%), knee (44%), ankle (17%) and shoulder (15%) joints. Patients with bilateral osteonecrosis in their hips were likely to have bilateral osteonecrosis in their knees, whereas patients without osteonecrosis in both hips were unlikely to have osteonecrosis in both knees ( p = .0299). Osteonecrosis was never evident in the ankle or shoulder joints when a patient did not have osteonecrosis in both hip and knee joints. Conclusion: In this study, MRI – as a screening method for multifocal osteonecrosis associated with glucocorticoid therapy – showed the sites affected first are hips and knees followed by ankles and shoulders. If osteonecrosis is absent in hip and knee joints, further screening of the ankles and shoulders is unnecessary. Any osteonecrosis observed in the hip and/or the knee joints warrants a second MRI screening of the ankles and shoulders.